Why Abbott Laboratories (ABT) stock moved
Abbott Laboratories (ABT) shares rose 1.0% to $101.72 as of July 21, 2026, a modest gain from the prior close of $100.68. BestStocks flagged the session as a major change for ABT. Below, we break down what changed for ABT, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
ABT climbed 1.0% to $101.72
ABT rose 1.0% in its latest session, moving from $100.68 to $101.72.
What it means for Abbott Laboratories investors
For Abbott Laboratories investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Positive 1.0% session move. Weighing against that: Abbott Laboratories (ABT) moved -3.42% from $92.11 to $88.96 on 2026-07-14; New SEC filing — review for material disclosures. Because the move outpaced peers, it looks driven by ABT-specific developments rather than a broad sector rotation. Wall Street's consensus price target sits at $122.29, implying +20.2% upside from $101.72. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 92 days out, the next report is the most likely near-term test of the move.
ABT price reaction
ABT last traded at $101.72, up $1.04 (+1.03%) from the previous close of $100.68. The session traded on 0.9× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median -1.2% over the same stretch, leaving ABT ahead of the group by 2.2 points. Over the past month the stock has ranged between $87.83 and $101.72, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Abbott Laboratories (ABT)
The consensus analyst price target on Abbott Laboratories (ABT) is $122.29, 20.2% above the recent $101.72. Over the past 90 days analysts logged 0 upgrades, 11 maintains, and 0 downgrades. Here is how the bullish and bearish cases on ABT line up.
The bullish case
- Wall Street's consensus price target of $122.29 implies +20.2% upside from $101.72.
- The Street's most bullish target is $145.00 (+42.5%).
- Material positive event.
- Positive 1.0% session move.
- Positive price momentum.
The bearish case
- The most bearish analyst target is $92.00 (-9.6%).
- Abbott Laboratories (ABT) moved -3.42% from $92.11 to $88.96 on 2026-07-14.
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for ABT
Frequently asked questions about ABT
Why did Abbott Laboratories (ABT) stock move?
ABT rose 1.0% to $101.72. No single company-specific catalyst was confirmed during the move window, and it looks like a company-specific move.
How much did ABT stock rise?
ABT gained 1.03% ($1.04) versus the prior close of $100.68, last trading at $101.72 on 0.9× average volume.
When is Abbott Laboratories's next earnings date?
ABT's next earnings report is estimated for 2026-10-21 — about 92 days away.
What is the analyst price target for ABT?
The consensus analyst price target for ABT is $122.29, about 20.2% above the current $101.72. Over the past 90 days, analysts recorded 0 upgrades, 11 maintains, and 0 downgrades.
Is the ABT move company-specific or sector-wide?
BestStocks classifies it as a company-specific move: the peer group moved a median -1.2% against ABT's +1.0%. ABT ranks top 1 of 7 peers.
How BestStocks tracks ABT
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared ABT-specific materiality thresholds, triggering an evidence check. It draws on 11 tracked change events for ABT, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.